ALAlphabet Inc.
Institutional investor · Portfolio as of Q4 2023
Top Holdings44 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
DEXCOM INC | 3.7M | $456.9M | 21.2% | $122.16 | +1.58% | 5 qtrssince 2022-Q4 | Increased 99 |
CROWDSTRIKE HOLDINGS INC - A | 1.3M | $327.7M | 15.2% | $120.06 | +112.66% | 5 qtrssince 2022-Q4 | Unchanged 0 |
UIPATH INC | 7M | $174.7M | 8.1% | $12.71 | +95.44% | 5 qtrssince 2022-Q4 | Decreased 0 |
VERVE THERAPEUTICS INC | 12.3M | $172.1M | 8.0% | — | — | 5 qtrssince 2022-Q4 | Increased 70 |
GITLAB INC | 2.6M | $166.7M | 7.7% | $43.53 | +44.63% | 5 qtrssince 2022-Q4 | Unchanged 0 |
REVOLUTION MEDICINES INC | 5.3M | $152M | 7.0% | $28.68 | 0.00% | 1 qtr | New 95 |
ARM Holdings PLC Sponsored ADR | 2M | $147.3M | 6.8% | $53.52 | +40.40% | 2 qtrssince 2023-Q3 | Unchanged 0 |
SNOWFLAKE INC-CLASS A | 535,604 | $106.6M | 4.9% | $143.54 | +38.64% | 5 qtrssince 2022-Q4 | Unchanged 0 |
PRIME MEDICINE INC | 11.9M | $105.1M | 4.9% | $18.58 | -52.31% | 5 qtrssince 2022-Q4 | Unchanged 0 |
FRESHWORKS INC | 4M | $94.8M | 4.4% | $14.71 | +59.69% | 5 qtrssince 2022-Q4 | Unchanged 0 |
PLANET LABS PBC | 31.9M | $78.9M | 3.7% | $4.35 | -43.22% | 5 qtrssince 2022-Q4 | Unchanged 0 |
INVIVYD INC | 5.7M | $22.4M | 1.0% | $1.50 | +162.67% | 5 qtrssince 2022-Q4 | Unchanged 0 |
RELAY THERAPEUTICS INC | 1.6M | $17.3M | 0.8% | $14.94 | -26.31% | 5 qtrssince 2022-Q4 | Unchanged 0 |
OSCAR HEALTH INC - CLASS A | 1.6M | $14.9M | 0.7% | $2.46 | +271.95% | 5 qtrssince 2022-Q4 | Decreased 0 |
RAPT Therapeutics Inc. | 540,270 | $13.4M | 0.6% | — | — | — | — |
SANA BIOTECHNOLOGY INC | 2.8M | $11.5M | 0.5% | $3.95 | +3.29% | 5 qtrssince 2022-Q4 | Unchanged 0 |
LYELL IMMUNOPHARMA INC | 5.9M | $11.4M | 0.5% | — | — | — | — |
BEAM THERAPEUTICS INC | 321,604 | $8.8M | 0.4% | $39.11 | -30.40% | 5 qtrssince 2022-Q4 | Unchanged 0 |
Desktop Metal Inc. | 11M | $8.3M | 0.4% | — | — | — | — |
MONTE ROSA THERAPEUTICS INC | 1.5M | $8.3M | 0.4% | $7.61 | -25.76% | 5 qtrssince 2022-Q4 | Unchanged 0 |
Alphabet Inc. manages $2.2B across 44 positions as of Q4 2023. Top holdings: DXCM (21.2%), CRWD (15.2%), PATH (8.1%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.
Added 1 new position, exited 2, increased 3, trimmed 3. Top move: DXCM (INCREASED, conviction 99). Portfolio: $2.2B across 44 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer